WELL Health Technologies

WELL-T

Analysis and Opinions about WELL-T

Signal
Opinion
Expert
Chart
BUY WEAKNESS
BUY WEAKNESS
April 26, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. No concerns for the stock except for the short term volatility. The short report will affect it short term, but management is committed with no sellers. Insiders own 16%. Attractive around $5.75. Unlock Premium - Try 5i Free

Show full opinionHide full opinion

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. No concerns for the stock except for the short term volatility. The short report will affect it short term, but management is committed with no sellers. Insiders own 16%. Attractive around $5.75. Unlock Premium - Try 5i Free

DON'T BUY
DON'T BUY
April 20, 2021
He's closely watching the telehealth sector, which leapt ahead years during this pandemic. He prefers Teledoc. WELL is growing by buying businesses and adding customers, but it's a strategy he doesn't like, so he's put WELL on the backburner, but if they integrate these new companies well, WELL will do extremely well.
Show full opinionHide full opinion
He's closely watching the telehealth sector, which leapt ahead years during this pandemic. He prefers Teledoc. WELL is growing by buying businesses and adding customers, but it's a strategy he doesn't like, so he's put WELL on the backburner, but if they integrate these new companies well, WELL will do extremely well.
James Telfser
Price
$7.030
Owned
No
BUY
BUY
March 19, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. They are in the midst of acquiring CRH. They will have more than $300M sales. Including expected growth, it looks much cheaper than it is. The company has lost money to date but is expected to make a profit this year. It must execute and is not risk free. Good growth potential. Unlock Premium - Try 5i Free

Show full opinionHide full opinion

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. They are in the midst of acquiring CRH. They will have more than $300M sales. Including expected growth, it looks much cheaper than it is. The company has lost money to date but is expected to make a profit this year. It must execute and is not risk free. Good growth potential. Unlock Premium - Try 5i Free

DON'T BUY
DON'T BUY
March 17, 2021
Canadian success story. Health technology play. A popular stock. Be cautious because of the valuation. Debatable if recent acquisition will be accretive. Trades at 35x forward EBITDA, so quite expensive.
Show full opinionHide full opinion
Canadian success story. Health technology play. A popular stock. Be cautious because of the valuation. Debatable if recent acquisition will be accretive. Trades at 35x forward EBITDA, so quite expensive.
Colin Stewart
Price
$8.000
Owned
No
COMMENT
COMMENT
March 10, 2021

WELL vs. TDOC He likes the industry, especially during Covid. A lot of efficiency gains have been unlocked with telehealth platforms. He prefers TDOC in the US, especially after its recent integration.

Show full opinionHide full opinion

WELL vs. TDOC He likes the industry, especially during Covid. A lot of efficiency gains have been unlocked with telehealth platforms. He prefers TDOC in the US, especially after its recent integration.

Shane Obata
Price
$8.130
Owned
No
HOLD
HOLD
March 5, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The market has shifted quickly recently. However, with an appropriate time frame, this stock should do fine. Nothing has changed fundamentally or at the company level. Though not risk free, the drop is market-related and not fundamental issues with the company. Unlock Premium - Try 5i Free

Show full opinionHide full opinion

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The market has shifted quickly recently. However, with an appropriate time frame, this stock should do fine. Nothing has changed fundamentally or at the company level. Though not risk free, the drop is market-related and not fundamental issues with the company. Unlock Premium - Try 5i Free

BUY
BUY
February 8, 2021

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The acquisition of CRH is expected to be highly synergistic. There will be cross selling opportunities and a substantial presence in the US. It will attract new investors as it gets bigger. Unlock Premium - Try 5i Free

Show full opinionHide full opinion

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The acquisition of CRH is expected to be highly synergistic. There will be cross selling opportunities and a substantial presence in the US. It will attract new investors as it gets bigger. Unlock Premium - Try 5i Free

BUY
BUY
December 7, 2020

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The US listing is generally positive. The move to be on the US index makes sense for a high growth company. Investors in the US are fine paying up front for future growth. Unlock Premium - Try 5i Free

Show full opinionHide full opinion

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. The US listing is generally positive. The move to be on the US index makes sense for a high growth company. Investors in the US are fine paying up front for future growth. Unlock Premium - Try 5i Free

SPECULATIVE BUY
SPECULATIVE BUY
November 11, 2020
Telehealth will solve some of the problems of escalating health care costs. It's the future. Telus Health is one way to play it. He likes WELL, but not for the faint of heart, big risk/reward. A lot of things have to go right, and you have to assume they'll be cashflow positive in the future. A name you do want to own.
Show full opinionHide full opinion
Telehealth will solve some of the problems of escalating health care costs. It's the future. Telus Health is one way to play it. He likes WELL, but not for the faint of heart, big risk/reward. A lot of things have to go right, and you have to assume they'll be cashflow positive in the future. A name you do want to own.
Greg Newman
Price
$7.140
Owned
Yes
DON'T BUY
DON'T BUY
September 22, 2020
Telemedicine is a very hot space, but can't accept the valuations (he's a value investor). They make good acquisitions. Many revenues come from clinics. All tech companies have sky-high valuations, betting on future sales and earnings. Not for the feint of heart. The valuation is too high.
Show full opinionHide full opinion
Telemedicine is a very hot space, but can't accept the valuations (he's a value investor). They make good acquisitions. Many revenues come from clinics. All tech companies have sky-high valuations, betting on future sales and earnings. Not for the feint of heart. The valuation is too high.
SPECULATIVE BUY
SPECULATIVE BUY
September 2, 2020

Getting some recognition with digital transformation of health. Had a nice bounce over the last few weeks. More on the risky side. Don't put all your eggs in. One of those names that, if you looked back 10 years from now, might be the next Shopify. Seems to be well run.

Show full opinionHide full opinion

Getting some recognition with digital transformation of health. Had a nice bounce over the last few weeks. More on the risky side. Don't put all your eggs in. One of those names that, if you looked back 10 years from now, might be the next Shopify. Seems to be well run.

Cole Kachur
Price
$6.180
Owned
No
BUY
BUY
September 2, 2020

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It continues to execute well with a solid management team. The company is well financed and is likely to profit from the expansion of the sector. Growth prospects are positive with committed insiders. Unlock Premium - Try 5i Free

Show full opinionHide full opinion

Billy Kawasaki’s Insights - Billy’s most-liked answers from 5i Research. It continues to execute well with a solid management team. The company is well financed and is likely to profit from the expansion of the sector. Growth prospects are positive with committed insiders. Unlock Premium - Try 5i Free

BUY
BUY
September 1, 2020

WELL Health vs. Cloud MD, and buy the warrants? Different companies in the same sector. He owns both and expects both to excel in the coming year. Cloud MD just released earnings, not as strong as he expected, but talked about future catalysts coming in the fall. WELL just announced an acquisition and got financing from their biggest shareholder, Lee Ka-Shing. Both are equally good. Warrants: you could do this, but the challenge is that both stocks have enjoyed huge runs and profit-taking could happen. You have a finite time before those warrants expire worthless or you decide to exercise the warrants--it's riskier, though offers a higher return. In contrast, you can just hold onto the stock.

Show full opinionHide full opinion

WELL Health vs. Cloud MD, and buy the warrants? Different companies in the same sector. He owns both and expects both to excel in the coming year. Cloud MD just released earnings, not as strong as he expected, but talked about future catalysts coming in the fall. WELL just announced an acquisition and got financing from their biggest shareholder, Lee Ka-Shing. Both are equally good. Warrants: you could do this, but the challenge is that both stocks have enjoyed huge runs and profit-taking could happen. You have a finite time before those warrants expire worthless or you decide to exercise the warrants--it's riskier, though offers a higher return. In contrast, you can just hold onto the stock.

Showing 1 to 13 of 13 entries
  • «
  • 1
  • »

WELL Health Technologies(WELL-T) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 8

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 3

Total Signals / Votes : 12

Stockchase rating for WELL Health Technologies is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

WELL Health Technologies(WELL-T) Frequently Asked Questions

What is WELL Health Technologies stock symbol?

WELL Health Technologies is a Canadian stock, trading under the symbol WELL-T on the Toronto Stock Exchange (WELL-CT). It is usually referred to as TSX:WELL or WELL-T

Is WELL Health Technologies a buy or a sell?

In the last year, 12 stock analysts published opinions about WELL-T. 8 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is BUY on WEAKNESS. Read the latest stock experts' ratings for WELL Health Technologies.

Is WELL Health Technologies a good investment or a top pick?

WELL Health Technologies was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for WELL Health Technologies.

Why is WELL Health Technologies stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is WELL Health Technologies worth watching?

12 stock analysts on Stockchase covered WELL Health Technologies In the last year. It is a trending stock that is worth watching.

What is WELL Health Technologies stock price?

On 2021-05-14, WELL Health Technologies (WELL-T) stock closed at a price of $6.82.